UY30932A1 - Miembros ligantes, especialmente moléculas de anticuerpo, para cxcl13, útiles para tratamiento de trastornos asociados con cxcl13, métodos productivos, composiciones y aplicaciones. - Google Patents
Miembros ligantes, especialmente moléculas de anticuerpo, para cxcl13, útiles para tratamiento de trastornos asociados con cxcl13, métodos productivos, composiciones y aplicaciones.Info
- Publication number
- UY30932A1 UY30932A1 UY30932A UY30932A UY30932A1 UY 30932 A1 UY30932 A1 UY 30932A1 UY 30932 A UY30932 A UY 30932A UY 30932 A UY30932 A UY 30932A UY 30932 A1 UY30932 A1 UY 30932A1
- Authority
- UY
- Uruguay
- Prior art keywords
- cxcl13
- useful
- binding members
- treatment
- antibody molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
Abstract
La presente invención se refiere a miembros ligantes, especialmente moléculas de anticuerpo, para CXCL13. Los miembros ligantes son útiles para el tratamiento de trastornos asociados con CXCL13, incluyendo trastornos artríticos como artritis reumatoides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89088807P | 2007-02-21 | 2007-02-21 | |
US90804107P | 2007-03-26 | 2007-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30932A1 true UY30932A1 (es) | 2009-01-30 |
Family
ID=39409730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30932A UY30932A1 (es) | 2007-02-21 | 2008-02-21 | Miembros ligantes, especialmente moléculas de anticuerpo, para cxcl13, útiles para tratamiento de trastornos asociados con cxcl13, métodos productivos, composiciones y aplicaciones. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20080199481A1 (es) |
EP (1) | EP2129691A1 (es) |
JP (1) | JP2010519280A (es) |
KR (1) | KR20090114464A (es) |
CN (1) | CN101636413A (es) |
AR (1) | AR065433A1 (es) |
AU (1) | AU2008217581A1 (es) |
BR (1) | BRPI0807631A2 (es) |
CA (1) | CA2677878A1 (es) |
EC (1) | ECSP099572A (es) |
IL (1) | IL200168A0 (es) |
MX (1) | MX2009008608A (es) |
PE (1) | PE20090161A1 (es) |
TW (1) | TW200846369A (es) |
UY (1) | UY30932A1 (es) |
WO (1) | WO2008102123A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3211094A3 (en) * | 2009-09-03 | 2017-11-01 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
MX353476B (es) * | 2010-09-02 | 2018-01-15 | Vaccinex Inc Star | Anticuerpos anti-cxcl13 y metodos para usarlos. |
CN106177930A (zh) | 2010-12-14 | 2016-12-07 | 吉安特科技股份有限公司 | 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途 |
CN102221607B (zh) * | 2011-03-29 | 2013-10-02 | 浙江大学医学院附属第一医院 | 一种抗体组合物及其应用 |
MX347454B (es) | 2011-07-22 | 2017-04-27 | Csl Ltd | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. |
EP2820045B1 (en) * | 2012-03-02 | 2018-08-22 | Vaccinex, Inc. | Methods for the treatment of b cell-mediated inflammatory diseases |
CN107478843A (zh) * | 2012-06-27 | 2017-12-15 | 吉安特科技公司 | 用于炎性疾病的抗‑cxcl9、抗‑cxcl10、抗‑cxcl11、抗‑cxcl13、抗‑cxcr3和抗‑cxcr5试剂 |
CN105408355A (zh) | 2013-01-31 | 2016-03-16 | 瓦克纳斯有限公司 | 用于提高免疫球蛋白a水平的方法 |
JP6531893B2 (ja) * | 2014-12-11 | 2019-06-19 | 国立大学法人 東京大学 | 濾胞性ヘルパーt細胞増加剤 |
CN104569431B (zh) * | 2015-01-04 | 2017-01-11 | 深圳市艾瑞生物科技有限公司 | 一种快速定量检测肌钙蛋白i的均相荧光免疫试剂组及其制备方法 |
CN104569409B (zh) * | 2015-01-04 | 2017-01-11 | 深圳市艾瑞生物科技有限公司 | 一种快速定量检测髓过氧化物酶的均相荧光免疫试剂组及其制备方法 |
CN104569374B (zh) * | 2015-01-04 | 2017-01-11 | 深圳市艾瑞生物科技有限公司 | 一种快速定量检测c‑反应蛋白的均相荧光免疫试剂组及其制备方法 |
BR112020010753A2 (pt) * | 2017-12-01 | 2020-11-24 | The Regents Of The University Of California | anticorpos anti-cxcr5 e composições e usos dos mesmos |
JP7098854B2 (ja) | 2018-09-18 | 2022-07-12 | アイ-エムエービー バイオファーマ ユーエス リミテッド | 自己免疫疾患およびがんを治療するための抗cxcl13抗体 |
US20220334132A1 (en) * | 2019-08-08 | 2022-10-20 | The Trustees Of Indiana University | Methods for identifying and treating urinary tract infections |
CN116782930A (zh) | 2020-06-11 | 2023-09-19 | 瓦西尼斯公司 | Cxcl13结合分子促进周围神经再生的用途 |
CN112521499B (zh) * | 2020-12-24 | 2022-10-25 | 四川大学 | 抗cxcl13抗体及其用途 |
WO2023042314A1 (ja) * | 2021-09-15 | 2023-03-23 | 和幸 吉崎 | 免疫異常性炎症性疾患を治療または予防するための組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
EP0811059A4 (en) | 1995-02-08 | 1998-04-01 | Human Genome Sciences Inc | BETA-11 HUMAN CHEMOKINE AND ALPHA-1 HUMAN CHEMOKINE |
CA2222280A1 (en) | 1995-06-05 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-11 and human chemokine alpha-1 |
CA2267131A1 (en) | 1996-10-04 | 1998-04-09 | Human Genome Sciences, Inc. | Therapeutic compositions and methods for treating disease states with leukocyte adhesion inhibitor-1 (lai-1), and chemokine beta-11 (ck.beta.-11) |
US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
EP1703282A1 (en) | 2005-03-15 | 2006-09-20 | BRD, vertreten durch das BM für Gesundheit und Soziale Sicherung, Letztvertreten durch den Präsidenten des Robert-Koch-Inst. | Method for ante mortem diagnosis of a TSE disease |
GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
WO2007124414A2 (en) * | 2006-04-21 | 2007-11-01 | Centocor, Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
-
2008
- 2008-02-19 US US12/033,145 patent/US20080199481A1/en not_active Abandoned
- 2008-02-20 AU AU2008217581A patent/AU2008217581A1/en not_active Abandoned
- 2008-02-20 CA CA002677878A patent/CA2677878A1/en not_active Abandoned
- 2008-02-20 CN CN200880005506A patent/CN101636413A/zh active Pending
- 2008-02-20 BR BRPI0807631-6A2A patent/BRPI0807631A2/pt not_active IP Right Cessation
- 2008-02-20 WO PCT/GB2008/000567 patent/WO2008102123A1/en active Application Filing
- 2008-02-20 PE PE2008000354A patent/PE20090161A1/es not_active Application Discontinuation
- 2008-02-20 TW TW097105868A patent/TW200846369A/zh unknown
- 2008-02-20 JP JP2009550751A patent/JP2010519280A/ja not_active Withdrawn
- 2008-02-20 MX MX2009008608A patent/MX2009008608A/es unknown
- 2008-02-20 EP EP08709453A patent/EP2129691A1/en not_active Withdrawn
- 2008-02-20 KR KR1020097019548A patent/KR20090114464A/ko not_active Application Discontinuation
- 2008-02-21 UY UY30932A patent/UY30932A1/es not_active Application Discontinuation
- 2008-02-21 AR ARP080100728A patent/AR065433A1/es unknown
-
2009
- 2009-07-30 IL IL200168A patent/IL200168A0/en unknown
- 2009-08-12 EC EC2009009572A patent/ECSP099572A/es unknown
- 2009-12-04 US US12/631,170 patent/US8182811B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20090114464A (ko) | 2009-11-03 |
AU2008217581A1 (en) | 2008-08-28 |
MX2009008608A (es) | 2009-09-16 |
ECSP099572A (es) | 2009-10-30 |
IL200168A0 (en) | 2010-04-15 |
US20100086942A1 (en) | 2010-04-08 |
PE20090161A1 (es) | 2009-04-30 |
EP2129691A1 (en) | 2009-12-09 |
BRPI0807631A2 (pt) | 2014-06-03 |
WO2008102123A1 (en) | 2008-08-28 |
CA2677878A1 (en) | 2008-08-28 |
TW200846369A (en) | 2008-12-01 |
CN101636413A (zh) | 2010-01-27 |
US20080199481A1 (en) | 2008-08-21 |
US8182811B2 (en) | 2012-05-22 |
JP2010519280A (ja) | 2010-06-03 |
AR065433A1 (es) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30932A1 (es) | Miembros ligantes, especialmente moléculas de anticuerpo, para cxcl13, útiles para tratamiento de trastornos asociados con cxcl13, métodos productivos, composiciones y aplicaciones. | |
UY30430A1 (es) | Compuestos | |
NZ598791A (en) | Anti-gcc antibody molecules and related compositions and methods | |
ATE554105T1 (de) | Veränderte antikörper | |
UA114611C2 (uk) | Пестицидні композиції і способи, що їх стосуються | |
BR112013020500A8 (pt) | anticorpo isolado, recombinante ou purificado | |
ECSP14013220A (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
ECSP10010475A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
ECSP12011879A (es) | Anticuerpo anti-tslp modificado por técnicas de ingeniería genética | |
BRPI0918648A2 (pt) | anticorpos multiespecíficos | |
EA201300819A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
MX340831B (es) | Composiciones pesticidas. | |
BR112013021433A2 (pt) | método de produção de metanol e/ou de hidrocarbonetos a partir de pelo menos uma matéria carbonada e instalação de produção de metanol e/ou de hidrocarbonetos a partir de pelo menos uma matéria carbonada | |
BR112012023015A2 (pt) | imunoensaios para lenalidomida e talidomida | |
CO6741157A2 (es) | Composiciones plaguicidas y procesos relacionados con dichas composiciones | |
DOP2010000369A (es) | Inmunoglobulinas con dominio variable dual y usos de la misma | |
DOP2011000333A (es) | Inmunoglobulina con dominio variable dual y usos de la mismas | |
DK2912071T3 (da) | Opslæmning omfattende stuk og prægelatineret stivelse med mellemviskositet, gipsplade fremstillet ud af denne opslæmning og fremgangsmåde til fremstilling af pladen | |
CR20110204A (es) | Moleculas de anticuerpo mejoradas | |
EA200900492A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
AR094872A1 (es) | Anticuerpos anti-tnf-anti-il-17 biespecíficos | |
CY1119173T1 (el) | Νεα μορια αναστολεα jnk | |
UY33703A (es) | Anticuerpos anti-il-23 | |
EA200970909A1 (ru) | Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов | |
MX2009008934A (es) | Proceso para la preparacion de algunas sulfiliminas sustituidas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170912 |